So much has been said and written about unethical behaviour amongst executives in the financial sector. This has been a source of embarrassment for many of them.
So much has been said and written about unethical behaviour amongst executives in the financial sector. This has been a source of embarrassment for many of them. If Pharma executives were put under similar scrutiny would we come out of the process better? |If not, we should proactively get our house in order before the inevitable happens
We must consider the fact that our industry is largely funded by pension funds i.e. public money. Particularly money largely sourced from the elderly population. It is only a matter of time before the voice of discontent grows stronger. Would we really pass the red face test?
blog comments powered by DisqusKevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs